Home
>
National Drug Code (NDC)
>
Treatment Set TS343825
Treatment Set TS343825 - 49288-0824-3 - (Treatment Set TS343825)
Drug Information of Treatment Set TS343825
| Product NDC: | 49288-0824 |
| Proprietary Name: | Treatment Set TS343825 |
| Non Proprietary Name: | Treatment Set TS343825 |
| Active Ingredient(s): | .01; .01; .01; .01; .01 g/mL; g/mL; g/mL; g/mL; g/mL & nbsp; Treatment Set TS343825 |
| Administration Route(s): | INTRADERMAL; SUBCUTANEOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Treatment Set TS343825
| Product NDC: | 49288-0824 |
| Labeler Name: | Antigen Laboratories, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA102223 |
| Marketing Category: | BLA |
| Start Marketing Date: | 19861031 |
Package Information of Treatment Set TS343825
| Package NDC: | 49288-0824-3 |
| Package Description: | 10 mL in 1 VIAL, MULTI-DOSE (49288-0824-3) |
NDC Information of Treatment Set TS343825
| NDC Code | 49288-0824-3 |
| Proprietary Name | Treatment Set TS343825 |
| Package Description | 10 mL in 1 VIAL, MULTI-DOSE (49288-0824-3) |
| Product NDC | 49288-0824 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Treatment Set TS343825 |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRADERMAL; SUBCUTANEOUS |
| Start Marketing Date | 19861031 |
| Marketing Category Name | BLA |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | ALTERNARIA ALTERNATA; ASPERGILLUS FUMIGATUS; CLADOSPORIUM CLADOSPORIOIDES; COCHLIOBOLUS SATIVUS; PENICILLIUM CHRYSOGENUM VAR. CHRYSOGENUM |
| Strength Number | .01; .01; .01; .01; .01 |
| Strength Unit | g/mL; g/mL; g/mL; g/mL; g/mL |
| Pharmaceutical Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient] |
